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Abstract
Background: Aspirin-exacerbated respiratory disease (AERD) refers to the development of bronchoconstriction in
asthmatics following the ingestion of aspirin. Although alterations in eicosanoid metabolites play a role in AERD, other
immune or inflammatory mechanisms may be involved. We aimed to identify proteins that were differentially expressed in
nasal polyps between patients with AERD and aspirin-tolerant asthma (ATA).
Methodology/Principal Findings: Two-dimensional electrophoresis was adopted for differential display proteomics.
Proteins were identified by liquid chromatography-tandem mass spectrometry (LC-MS). Western blotting and
immunohistochemical staining were performed to compare the amount of fatty acid-binding protein 1 (FABP1) in the
nasal polyps of patients with AERD and ATA. Fifteen proteins were significantly up- (seven spots) or down-regulated in the
nasal polyps of patients with AERD (n=5) compared to those with ATA (n=8). LC-MS revealed an increase in seven proteins
expression and a decrease in eight proteins expression in patients with AERD compared to those with ATA (P=0.003–0.045).
FABP1-expression based on immunoblotting and immunohistochemical analysis was significantly higher in the nasal polyps
of patients with AERD compared to that in patients with ATA. FABP1 was observed in epithelial, eosinophils, macrophages,
and the smooth-muscle cells of blood vessels in the polyps.
Conclusions/Significance: Our results indicate that alterations in 15 proteins, including FABP1, may be related to the
development of AERD.
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Introduction
Aspirin-exacerbated respiratory disease (AERD) refers to the
development of bronchoconstriction in asthmatics individuals
following the ingestion of aspirin (acetylsalicylic acid) or other non-
steroidal anti-inflammatory drugs. This syndrome is characterized
by the ‘‘aspirin triad,’’ which consists of aspirin hypersensitivity,
bronchial asthma, nasal polyposis, and chronic hyperplastic
eosinophilic sinusitis [1,2]. As is true for other asthmatic
individuals, the airways of patients with AERD show signs of
persistent inflammation with marked eosinophilia, epithelial
disruption, cytokine production, and the up-regulation of
inflammatory molecules. The over- or under-production of critical
mediators, including leukotrienes, lipoxins, thromboxane, and
prostaglandins, in the metabolism of arachidonic acid probably
accounts for this susceptibility to aspirin. Variation within the
genes of the arachidonate pathway is responsible for changes in
the production and metabolism of these mediators. Polymor-
phisms in such genes as LTC4S [3], ALOX5 [4], PTGER2 [5],
PTGER3 [6], TBXA2R [7] and CYSLTR2 [8] have been revealed
to be associated with AERD.
ASA and sodium salicylate have been reported to inhibit
activation of the transcription factors NFKB [9]. ASA also regulate
IL4 expression by altering the availability of transcription factors
to the regulatory elements in the IL4 promoter [10] and inhibit
IL4– and IL13–induced activation of STAT6 [11]. These
observations suggest that aspirin regulates a more complex
network of biochemical and cellular events than was initially
thought. To characterize this network, high-throughput tech-
niques, including proteomics and gene expression analysis, are
needed to identify genes related to AERD. Three reports have
utilized microarray technology to examine gene expression and
methylation patterns in nasal polyp tissues from AERD [12,13,14].
These reports indicated that nasal polyps have characteristic
transcriptional signatures compared with normal tissues; however,
no global studies of protein expression in nasal polyps have been
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22711undertaken for AERD. In this study, we adopted a proteomics-
based approach to investigate the pathobiology of and to develop a
marker for aspirin hypersensitivity.
Results
2-DE of nasal polyps and protein identification in ATA
and AERD samples by LC-MS
The nasal polyp samples were separated in the first dimension
on IPG gel strips over a pH range of 3 to 10, followed by
separation in the second dimension by 7.5–20% homogeneous
SDS-PAGE (Figure 1). After Coomassie blue staining and image
analysis, a mean number of 984 spots (range 853–994) in the ATA
samples and 907 spots (range 790–984) in the AERD samples were
detected in 1 mg of nasal polyp. The relative intensities were
significantly higher in seven spots and lower in eight spots in the
AERD samples compared to the ATA samples. These spots were
excised from the gels and incubated with trypsin for in-gel
digestion and then identified by LC-MS. All of the identified spots
were localized between a pH of 4 and 8 with a molecular mass
range of 10 to 150 kDa (Figure 1A). The relative intensities (%) of
the spots are expressed as median values and interquartile ranges
for each group (Figure 1B). Fifteen proteins showed significant
differences in relative intensity between the two groups according
to the Mann-Whitney U-test (p,0.05). The results of these
analyses are summarized in Table 1. The relative intensity of spot
#1 (chaperonin group 2) was ten times higher in the AERD
patients than in the ATA patients (p=0.003). FABP1, carbamyl
phosphate synthetase I, aldehyde dehydrogenase 4A1 precursor,
betaine-homocysteine methyltransferase isoform CRA b, immu-
noglobulin gamma light chain, and glyceraldehyde-3-phosphate
dehydrogenase were more abundant in the AERD samples than in
the ATA samples. In contrast, the relative intensities of the other
eight spots were significantly lower in the AERD group than in the
ATA group (Figure 1 and Table 1). They were identified as beta
actin, transketolase, transketolase variant, heat shock 70 kDa
protein 9 precursor, UDP-glucose pyrophosphorylase 2 isoform a,
heat-responsive protein 12, KIAA1361 protein, and zinc finger
protein 609 (Table 1).
Expression of FABP1 in nasal polyps from AERD and ATA
patients
To investigate whether FABP1 expression was altered in nasal
polyps, we performed Western blotting and immunohistochemical
staining using nasal polyps obtained from similar subjects with
ATA (n=5) and AERD (n=8). A 15.7 kDa band representing
FABP1 was present by Western blotting in both groups (Figure 2A).
The density normalized with beta actin was significantly higher in
the nasal polyps from the AERD patients than in those from the
ATA patients (0.8460.09 vs. 0.1360.03, respectively, p=0.009;
Figure 2B). Immunohistochemical staining of serial sections for
FABP1, SMA, CD163, and MBP was performed on 4-mm sections
of paraffinized nasal polyp samples. Immunohistochemical
staining showed markedly increased expression of FABP1 in the
nasal polyps of the AERD patients compared to those with ATA.
FABP1 was strongly expressed in the epithelial cells, CD 163
positive macrophages, MBP positive eosinophils, and SMA
positive smooth muscle cells of blood vessel (Figure 3).
Plasma concentration of FABP1 in subjects with AERD or
ATA
The plasma concentration of FABP1 in the AERD and ATA
subjects was found to be similar by ELISA (17,24562,607 pg/ml
vs. 15,30461,476 pg/ml, respectively, p=0.880; Figure 4B). The
normalized concentration of FABP1 (with total protein) was
similar in both groups (0.1860.04 pg/ug vs. 0.1660.02 pg/ug,
respectively, p=0.545; Figure 4C).
Discussion
In the present study, we use 2-D gels to distinguish AERD from
ATA based on protein abundance. We identified 15 proteins that
exhibited differential expression between ATA and AERD
patients. In a previous study using plasma from patients with
AERD or ATA, we found that the amounts of three proteins
(complement C3 fragments, apolipoprotein, and modified albu-
min) differed between the two groups [15]. Although complement
components are regarded as a candidate participant in the
pathogenesis of AERD, additional searches for other molecular
makers of AERD have been done using new biosources.
AERD is characterized by extensive mucosal inflammation in
the lower (asthma) and upper (rhinitis and nasal polyps) airways
[2]. The nasal polyps of AERD patients show similar pathological
characteristics, including the infiltration of inflammatory cells into
the bronchial mucosa [16]. The inflammatory cell infiltrate sets up
an extensive network of cellular interactions, which are thought to
promote nasal polyp proliferation. Thus, nasal polyps are a good
biosource for the study of AERD. To identify new markers to
better understand the molecular basis of AERD, we adopted a
proteomics-based approach. This is the first report to show, in a
single map, the different proteins expressed in nasal polyp tissues
from patients with AERD or ATA.
We found 15 spots that were differentially expressed in AERD
and ATA patients. LC-MS showed that, in contrast to the changes
in complement proteins and apolipoproteins in the plasma, several
other types of proteins were expressed differentially in the nasal
polyps. The amount of FABP1 was six times higher in the AERD
samples than in the ATA samples (p=0.007) based on 2-DE, and
eight times higher by Western blot analysis. Our immunohisto-
chemical results indicate that FABP1 is expressed more abun-
dantly in the nasal polyps of AERD patients. In particular, FABP1
strongly expresses in epithelial cells, macrophages, eosinophils, and
blood vessel smooth muscle cells.
Fatty acid trafficking in cells is a complex and dynamic process
that affects many aspects of cellular function. Linoleic and
arachidonic acids can be metabolized to a diverse and large
family of bio-active lipid mediators called eicosanoids, which may
function as pro- and anti-inflammatory mediators [17]. FABPs are
small, abundant cytoplasmic proteins that reversibly bind
saturated and unsaturated long chain fatty acids, eicosanoids,
and other lipids. FABPs play a role in trafficking of intracellular
arachidonic acid metabolism and in the conversion of fatty acids to
eicosanoid intermediates and in the stabilization of leukotrienes
[18]. Among the mediators of the eicosanoid pathway, LTA4 is an
intermediate in the formation of biologically active leukotrienes.
LTA4 in the binding site of FABP is stabilized for subsequent
biochemical processing to LTB4 and cysteinyl leukotrienes [18].
The striking stabilization of LTA4 by various FABP proteins
suggests that this family plays a central and previously unrecog-
nized role in leukotriene biosynthesis in the cell.
An additional function of FABP is the reduction of 15-
lipoxygenase (LO) activity [19]. The end products of 15-LO are
lipoxin and aspirin-triggered lipoxin, which have anti-inflamma-
tory actions. Taken together, the elevation of FABP may switch
the tissue environment to LTB4 or cysteinyl leukotriene over-
production and down-regulation of the lipoxin family, which has
been demonstrated in nasal polyps or airways of AERD patients.
FABP1 Is Related with Development of AERD
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FABP1 is significantly elevated in the nasal polyps of AERD
patients compared to ATA patients. This finding highlights the
need for a renewed focus on candidate modulators of inflamma-
tory responses and arachidonic acid metabolism by FABP1.
Because L-FABP1 is produced mainly by the liver, it has been
used as a marker of liver injury. Recently, it was shown that L-
FABP1 levels were altered in patients with septic shock and in
those with nephropathy [20]. Lipid peroxidation and lipid
accumulation could be the primary cause of FABP1 excretion
into urine, and urinary shedding of FABP1 may protect against
tubular cell injury. This prompted us to measure FABP1 in the
plasma of our subjects. The levels were similar in both types of
patients. This indicates that plasma FABP1 may have no effect on
the level in nasal polyps of the subjects in the present study.
The reason for the increase in FABP1 in the nasal polyps of the
AERD patients is unknown. In addition, it is unknown whether
the elevation in FABP1 is the cause of aspirin hypersensitivity or
the result of extensive inflammation in the nasal polyps of patients
with AERD. FABPs themselves are controlled by transcription
factors, including the PPAR family [21]. Interestingly, aspirin up-
regulates PPAR alpha/gamma in various cells via the over-
production of eicosanoid metabolites, including 15-hydroxyeico-
satetraenoic acid (15-HETE), and 15-deoxy-12, 14-prostaglandin
J2 (15d-PG J2). Recently, a polymorphism in the gene encoding
PPAR gamma was revealed to be associated with aspirin
hypersensitivity [22]. Taken together, over-production of the
PPAR family via enhanced 15-HETE production in AERD may
induce FABP over-expression in the airways leading to exagger-
ated conversion to cysteinyl leukotrienes from stabilized LTA4-
FABP complexes.
Other proteomic studies have been performed on the nasal
polyps of patients with chronic sinusitis using 2-DE, and several
proteins expressed differentially between chronic sinusitis and
normal mucosa [23,24] before and after steroid treatment have
been identified [25]. Although 20 to 30 differentially expressed
Table 1. List of differentially expressed proteins identified by LC-MS.
No. Protein name Accession No. Determined sequence MW(kDa)
Relative
intensity P-value Function
PI ATA AERD
1 Chaperonin 31542947 R.IQEIIEQLDVTTSEYEK.E 27.9/5.7 0.022,0.223 0.003 Protein folding
2 FABP1 116284334 K.YQLQSQENFEAFMK.A 15.7/6.4 0.065,0.389 0.007 Fatty acid
meabolism
3 Beta actin 4501885 K.DLYANTVLSGGTTMYPGIADR.M 50.1/5.4 0.191.0.036 0.025 Cytoskeleton
4 Transketolase 37267 K.SKDDQVTVIGAGVTLHEALAAAELLK.K 50.0/4.1 0.040.0.013 0.018 glycolysis
5 Carbamyl phosphate
synthetase I
219553 K.GYSFGHPSSVAGEVVFNTGLGGYPEAITDPAYK.G 24.8/5.2 0.030,0.053 0.045 Energy
metabolism
6 Transketolase variant 62898960 K.SKDDQVTVIGAGVTLHEALAAAELLK.K 50.0/5.4 0.063.0.043 0.025 glycolysis
7 Heat shock 70 kDa
protein 9 precursor
24234688 K.VIAVYDLGGGTFDISILEIQK.G 27.3/5.4 0.138.0.053 0.005 Anti-inflammatory
8 UDP_glucose
pyrophosphorylase
2 isoform a
48255966 K.TLDGGLNVIQLETAVGAAIK.S 80.7/5.3 0.120.0.053 0.013 Glucose transfer
9 Aldehyde
dehydrogenase 4A1
precursor
25777734 K.ETLQLVDSTTSYGLTGAVFSQDKDVVQEATK.V 12.9/7.2 0.094,0.196 0.01 Proline
degradation
10 Betaine-homocysteine
methyltransferase,
isoform CRA b
119616238 R.LNAGEIVIGDGGFVFALEK.R 121.04/5.1 0.043,0.074 0.018 methyl transfer
11 Ig c light chain 34427 K.LLIYSNNQRPSGVPDR.F 28.8/7.3 0.023,0.053 0.018 Inflammatory
12 Glyceraldehydes-
3-phosphate
dehydrogenase
31645 K.WGDAGAEYVVESTGVFTTMEK.A 61.2/5.3 0.022,0.050 0.034 Energy
metabolism
13 Heat-responsive
protein 12
5032215 K.TTVLLADINDFNTVNEIYK.Q 63.3/4.4 0.042.0.021 0.045 unknown
14 KIAA1361 protein 7243103 K.FQQHIQAQQK.K 38.3/4.4 0.208.0.076 0.025 microtubule
affinity regulating
kinase kinase
15 Zinc finger protein 609 71725360 K.QKPSIPPTLTK.A 21.5/4.2 0.092.0.033 0.013 unknown
doi:10.1371/journal.pone.0022711.t001
Figure 1. Photographs of two-dimensional electrophoresis (2-DE) separation of nasal polyps proteins obtained from ATA (n=8)
and subjects with AERD (n=5). (A) one ATA, and one patient with AERD. Nasal polyp proteins (1 mg) were focused on a pH 3–10 immobilized pH
gradient strip and then separated by 7.5–20% gradient SDS-PAGE and visualized as described in the Methods. Protein spots identified by LC-MS
(arrows) are labeled with numbers. Spot #2 is enlarged in small boxes. (B) The Y-axis of each graph represents the relative intensity of the spot (%). P-
values represent the difference between the ATA and AERD samples.
doi:10.1371/journal.pone.0022711.g001
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demonstrated. The reason for this may be the fact that aspirin
sensitivity is limited to about 30% of nasal polyposis cases [2].
Another interesting finding is the change in chaperones in the
AERD samples compared to the ATA samples. The relative
intensity of chaperonins following 2-DE was ten times higher in
the AERD samples than in the ATA samples. Chaperonins are
protein complexes that assist the folding of nascent, non-native
polypeptides into their native and functional state. Molecular
chaperones such as Hsp70 and TCP-1 ring complex (TRiC)/
chaperonin containing TCP-1 (CCT) are implicated as potent
modulators of misfolding diseases. These chaperones suppress the
toxicity of disease proteins and modify early events in the
aggregation process in a cooperative and sequential manner,
reminiscent of their functions in de novo protein folding. The
cytosolic stress pathway or heat shock response results in the nearly
instantaneous induction of the expression of such chaperones as
heat shock proteins [26]. In the present study, the levels of heat
shock 70 kDa protein 9 precursor and heat-responsive protein 12
were two times higher in ATA than in AERD samples. The
elevated cytoplasmic Hsp70 levels are thought to play a protective
role against cell damage induced by exogenous stresses, including
heat shock, tumor necrosis factor, oxidative stress, cytostatic drugs,
and radiation. After treatment with a nontoxic dose of ASA,
Hsp70 membrane expression was up-regulated, especially as
membrane-bound Hsp70. Thus, the change in chaperonins in
the present study may indicate the altered celluar response of nasal
polyps to aspirin in AERD as compared to ATA. Alternatively,
disease processes themselves might cause, or worsen, the
chaperone deficiency. The DNA binding activity of the transcrip-
tion factor HSF-1 decreases with age in rat hepatocytes, causing a
continuous decline in the ability to induce the expression of genes
encoding chaperones during the cytosolic stress response [26]. In
the present study, the mean age was not different between the
AERD and ATA patients, which can exclude the possibility of age
effects on Hsp70 levels. Another interesting finding is the change
in several intracellular enzymes, including carbamyl phosphate
synthetase I, aldehyde dehydrogenase 4A1 precursor, betaine-
homocysteine methyltransferase isoform CRA b, transketolase,
UDP-glucose pyrophosphorylase 2 isoform a, and glyceraldehyde-
Figure 2. Comparison of FABP1 expression in ATA and AERD
patients. FABP1 abundance was measured in nasal polyp extract
lysates of ATA (n=3) and AERD (n=3) patients using a mouse anti-
human FABP1 monoclonal antibody. (A) Representative figure and (B)
bar graph of the Western blot analysis of plasma from AERD and ATA
samples.
doi:10.1371/journal.pone.0022711.g002
Figure 3. Representative figure showing the immunohisto-
chemical analysis of nasal polyps from ATA (n=3) and AERD
(n=3) patients. A mouse anti-human FABP1 monoclonal antibody
(1:100 dilution), goat anti-human CD163 polyclonal antibodies (1:100
dilution), goat anti-human MBP polyclonal antibodies (1:100 dilution),
and a mouse anti-human alpha smooth muscle actin monoclonal
antibody (1:50, clone 1A4, DAKO, Glostrup, Denmark) were used.
Magnification: 4006.
doi:10.1371/journal.pone.0022711.g003
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transketolase and UDP-glucose pyrophosphorylase 2 isoform a
were increased in AERD.
Nitric oxide (NO) is a well-known active factor in endothelial-
derived relaxing factor. Carbamoyl phosphate synthetase 1 (CPS1)
is an enzyme that catalyzes the production of carbamoyl
phosphate, a precursor of arginine and NO [27]. Thus, the
CPS1 affects the L-citrulline/L-arginine cycle and subsequent NO
production. The amount of CPS1 was about 150% higher in the
AERD samples than in the ATA samples in the present study.
Interestingly, numerous dilated blood vessels were observed in the
AERD samples compared to the ATA samples, which provides
indirect evidence of a possible role for CPS1 in the nasal polyps of
AERD patients. Aldehyde dehydrogenase 4A1 precursor, betaine-
homocysteine methyltransferase isoform CRA b, transketolase,
UDP-glucose pyrophosphorylase 2 isoform a, and glyceraldehyde-
3-phosphate dehydrogenase were differentially expressed in the
AERD and ATA patients. Aldehyde dehydrogenase 4A1 precur-
sor is related to a mitochondrial matrix NAD-dependent
dehydrogenase, which catalyzes the second step of the proline
degradation pathway, converting pyrroline-5-carboxylate to glu-
tamate [28]. Betaine-homocysteine methyltransferase 2 is a sulfur-
containing amino acid that plays a crucial role in methylation
reactions [29]. Transketolase is a thiamine-dependent enzyme that
links the pentose phosphate pathway to the glycolytic pathway
[30]. UDP-glucose pyrophosphorylase 2 isoform a plays an
important intermediary role in mammalian carbohydrate inter-
conversions [31]. These findings indicate the possibility of
alterations in energy metabolism in the nasal polyps of AERD
patients compared to ATA patients.
In summary, to identify nasal polyp proteins that were
differentially expressed between AERD and ATA patients, we
performed 2-DE with LC-MS. Seven proteins were significantly
up-regulated while eight proteins were down-regulated in the nasal
polyps of AERD patients (n=5) compared to ATA patients (n=8).
Among them, FABP1 levels were significantly higher in the nasal
polyps of the AERD patients compared to the ATA patients based
on our Western blot results. Immunohistochemical staining
showed strong staining in the nasal polyps of the AERD samples
compared to the ATA samples. However, the plasma FABP1
levels were similar in both. This indicates that an increase in
FABP1 abundance in nasal polyps may be related to the
development of AERD and may be a useful marker for diagnostic
and therapeutic trials.
Figure 4. Comparison of FABP1 levels in plasma from AERD (n=10) and ATA (n=10) patients. (A) Total protein, (B) FABP1, and (C)
normalized FABP1 concentrations with total plasma protein.
doi:10.1371/journal.pone.0022711.g004
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Ethics statement
Consent to participate in the study was obtained in writing from
all subjects. The protocols used in this study were approved by the
Soonchunhyang Bucheon Hospital’s ethics committee. Thirteen
nasal polyp tissues were obtained from the biobank at the Genome
Research Center for Allergy and Respiratory Diseases (Soon-
chunhyang Bucheon Hospital), South Korea.
Subjects
All patients met the criteria for asthma definition by the Global
Initiative for Asthma (GINA) guidelines [32]. All patients had a
history of dyspnea and wheezing during the previous twelve
months plus one of the following: 1).12% increase plus 200 mL
following inhalation from a short-acting bronchodilator, or
2),10 mg/mL PC20 methacholine. Twenty-four common inhal-
ant allergens (e.g., dust mites [Dermatophagoides farinae and D.
pteronyssinus], Aspergillus, cat fur, dog fur, cockroaches, grasses, trees,
and ragweed pollen) (Bencard Co. Ltd., Brentford, UK) were used
for skin prick tests. Atopy was defined as having a wheal reaction
either equal to or greater than histamine or 3 mm in diameter.
Total IgE was measured using the CAP system (Pharmacia
Diagnostics, Uppsala, Sweden). The asthmatics had experienced
no exacerbation of their condition or a respiratory tract infection
during the six weeks preceding the oral aspirin challenge (OAC).
The reactions of the patients to the OAC were categorized as
follows: $15% decrease in FEV1 or naso-ocular reactions (AERD)
and ,15% decrease in FEV1 without naso-ocular or cutaneous
reactions (ATA). OAC was performed with increasing doses of
aspirin using methods slightly modified from those described
previously [10,33,34]. Briefly, patients with a history of aspirin
hypersensitivity were given 30 mg orally. Respiratory and nasal
symptoms, blood pressure, external signs (urticaria and angio-
oedema) and FEV1 were documented every 30 min for a period of
1.5 h. In the absence of any symptom or sign suggesting an
adverse reaction after 1.5 h, increasing dosages of aspirin (60 mg,
100 mg, 300 mg, and 400 mg) were administered and the same
measurements were repeated every 1 h until the patient developed
the reaction. Those having no history were started on 100 mg of
aspirin and gradually increased the dosage of aspirin as 200 mg,
350 mg, and 450 mg until the patient developed the reaction. If
no reaction occurred 4 h after the final dose, the test was deemed
negative. Aspirin-induced bronchospasm, reflected by a decline
(%) in FEV1, were calculated as the pre-challenge FEV1 minus the
post-challenge FEV1 divided by the pre-challenge FEV1. OAC
reactions were categorized into three groups as follows: (1) 15% or
greater decrease in FEV1 or nasal reactions (aspirin-intolerant
asthma [AERD]) or (2) less than 15% decrease in FEV1 without
naso-ocular or cutaneous reactions (aspirin-tolerant asthma
[ATA]). (3) less than 15% decrease in FEV1 with cutaneous
reactions (aspirin-induced urticaria) [AIU]).
Peripheral venous blood was obtained before OAC. Peripheral
venous blood was collected before aspirin challenge. Peripheral
blood mononuclear cells were separated on Ficoll -Hypaque
solution. All subjects gave informed consent to participate in the
study. The protocols were approved by the local ethics committees
of hospital. Diagnoses of nasal polyps and chronic rhinosinusitis
were made based on the patients’ symptoms as assessed from their
documented medical histories, the presence of endoscopically
visible nasal polyps arising from the middle nasal meatus, and
involvement of the ethmoidal and maxillary sinuses as visualized
by limited CT scanning of the paranasal sinuses. The clinical
characteristics of the subjects are summarized in Table 2. All
polyps were kept at 280uC until needed. Consent to participate in
the study was obtained in writing from all subjects. The protocols
used in this study were approved by the Hospital’s ethics
committee.
Two-dimensional electrophoresis (2-DE), protein
identification by nano liquid chromatography-tandem
mass spectrometry (LC-MS), and a database search
2-DE was performed using Immobiline DryStrips (24 cm,
pH 3–10, pH 3–7; Amersham Biosciences, Uppsala, Sweden) for
isoelectric focusing (IEF). DryStrips were first rehydrated in
450 mL of rehydration buffer containing 8 M urea, 2% CHAPS,
13 mM DTT, 1.2% IPG buffer, and a trace of bromophenol blue
then mixed with each sample. IEF was carried out for a total of
146 kVh using the IPGphore system (Amersham Biosciences) with
1 mg of nasal polyp. Following IEF, the gel strips were
equilibrated twice for 10 min with gentle shaking in equilibration
buffer containing 50 mM Tris-HCl buffer (pH 8.8), 6 M urea,
20% glycerol, 0.1% SDS, and 1% DTT. In the second
equilibration buffer, DTT was replaced with 2.5% iodoacetamide
to remove excess DTT. After equilibration, the proteins were
separated on 5–18.5% SDS polyacrylamide gels using the Ettan
Dalt II system (Amersham Pharmacia Biotech, Inc., Uppsala,
Sweden). At the end of each run, the gel was stained with
Coomassie brilliant blue G-250. Digitized images of the stained
gels were analyzed using the analysis program imagemaster 2D
(version 4.0; Amersham Pharmacia Biotech, Inc.). Coomassie-
stained spots on the gels of thirteen subjects were quantified on the
basis of the normalized volume (i.e., the spot volume divided by
the total sum of all spot volumes.).
Differentially expressed protein spots were excised from the 2-D
gels, cut into smaller pieces, and digested with trypsin (Promega)
[15,35]. LC-MS was performed using Agilent Nanoflow Proteo-
mics Solution and the Agilent 1100 Series nano LC system for
MS/MS coupled through an orthogonal nanospray ion source to
an Agilent 1100 Series LC/MSD Trap XCT ion trap mass
spectrometer. The nano LC system was operated in sample
enrichment/desalting mode with a ZORBAX 300SB-C18 enrich-
ment column (0.3650 mm, 5 um). Chromatography was per-
formed using a ZORBAX 300SB-C18 (75 um6150 mm) nano-
column. The column was eluted with a gradient beginning with an
Table 2. Clinical characteristics of the study subjects.
ATA AERD
No 8 5
Age, yr (mean 6 SE) 51.966.6 43.863.2
Sex (M/F) 4/4 2/3
Smoker (%) 25% -
Height (cm) 164.263.0 163.661.9
Weight (kg) 63.663.4 63.464.5
FVC (%, predicted) 96.766.5 89.864.4
FEV1 (%, predicted) 104.069.4 87.666.4
*
Positive skin test (%)
{ 50 60
Values are mean 6 SE. P-values are obtained using the t-test or the x
2-test
between AERD and ATA.
ATA: aspirin tolerant asthma, AERD : aspirin-exacerbated respiratory disease,
*P,0.05 compared with ATA.
{D.f, D.p, Strawdust, Haydust, Cockroach mix, Chrysanthemum P, Aster P, Cat
fur, Ragweed polle.
doi:10.1371/journal.pone.0022711.t002
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acetonitrile) and 97% solvent A (0.1% formic acid in water) for
5 min. The gradient mixture was then changed to 10% B over
5 min (from 5 to 10 min), to 45% B over 40 min (10 to 50 min), to
90% B (isocratic) for 5 min (55 to 60 min), and to 3% B over
1 min (60 to 61 min). Finally, the column was washed with 3% B
for 10 min.
The LC/MSD Trap XCT was operated in the unique peptide
scan auto-MS mode. The ionization mode was positive nanoelec-
trospray with an Agilent orthogonal source. The drying gas flowed
at 5 L/min at a temperature of 300uC. Vcap was typically 1,800–
1,900 V with skim 1 at 30 V; the capillary exit was offset at 75 V.
The trap drive was set at 85 V with averages of one or two. Ion
charge control was on with a maximum accumulation time of
150 ms; the smart target was 125,000 and the MS scan range was
300–2,200. Automatic MS/MS was performed in ultrascan mode
with the number of parents two, averages of two, a fragmentation
amplitude of 1.15 V, SmartFrag on (30–200%), active exclusion
on (after two spectra for 1 min), prefer +2 on, MS/MS scan range
of 100–1,800, and ultrascan on. Each acquired spectrum was
searched against the non-redundant protein sequence database
using Spectrum Mill software.
Western blotting and immunohistochemical staining of
nasal polyps for FABP1 expression
FABP1 expression was analyzed by Western blotting and
immunohistochemical staining with a mouse anti-human FABP1
monoclonal antibody. The protein samples were fractionated by
15% SDS-PAGE and transferred to nitrocellulose membranes
(Amersham Pharmacia Biotech, Inc.). The membranes were
incubated in a blocking solution containing a 1:500 dilution of
mouse anti-human FABP1 monoclonal antibody (Abcam, Cam-
bridge Science Park, Cambridge, UK) and then incubated with
blocking solution containing a 1:5,000 dilution of horseradish
peroxidase-conjugated polyclonal anti-mouse IgG antibodies.
Enhanced chemiluminescence (ECL) detection was performed
according to the manufacturer’s instructions (Boehringer Mann-
heim, Mannheim, Germany). For the immunohistochemical
analysis of FABP1, nasal polyp tissue on the slides was treated
with 0.3% H2O2 for 20 min to block endogenous peroxidase and
then incubated at 4uC overnight with a mouse anti-human FABP1
monoclonal antibody (1:100 dilution; Abcam), goat anti-human
CD163 polyclonal antibodies (1:100 dilution; Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), goat anti-human
MBP polyclonal antibodies (1:100 dilution; Santa Cruz Biotech-
nology Inc.), and a mouse anti-human alpha smooth muscle actin
monoclonal antibody (1:50, clone 1A4, DAKO). The slides were
incubated with an ABC kit (Vector Laboratories, Burlingame, CA,
USA), and the color developed with 3,39-diaminobenzidine
tetrachloride (Zymed Laboratory Inc., South San Francisco, CA,
USA). Other immunohistochemical analyses included the use of a
mouse anti-human alpha smooth muscle actin monoclonal
antibody (1:50, clone 1A4, DAKO). For signal detection, the
sections were incubated with the DAKO Real EnVision Detection
System (K5007) according to the manufacturer’s protocol.
Staining for the expression of CD163, MBP, and alpha smooth
muscle actin was performed for macrophages, eosinophils, and
smooth muscle or myofibroblasts, respectively.
Measurement of plasma FABP1 by ELISA
Plasma FABP1 was measured using a quantitative sandwich
enzyme immunoassay kit according to the manufacturer’s
instructions (HyCult Biotechnology, Uden, The Netherlands).
The lower limit of detection for FABP1 was 102 pg/mL. Values
below this limit were assumed to be zero for statistical analysis.
The inter- and intra-assay coefficients of variance were below
15%.
Statistical analysis
Statistical analysis was performed with SPSS 8.0. For the
analysis of spot intensity on the 2-D gels and determination of the
FABP1 concentration, the Mann-Whitney test (two-sample rank
sum test) was used to analyze differences between the two groups
(AERD vs. ATA). All data are expressed as the mean 6 SE;
significance was defined as p,0.05.
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